Search
VolitionRX Ltd
VNRXAdd to Watchlist
1.400USD
+0.020+1.47%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
153.47MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.47%
5 Days
+9.38%
1 Month
-30.00%
6 Months
-74.36%
Year to Date
-72.61%
1 Year
+89.19%
Key Figures
1.350Open
1.460High
208.73KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.19%Turnover Ratio
1.360Prev. Close
1.320Low
201.75KTurnover
LossP/E Static
-4.43P/B
0.00%Div Yield TTM
-281.72%ROA
18.80052wk High
1.76Volume Ratio
-26.97MNet Profit
109.62MShares
-4.2173EPS TTM
1.06Beta
-5396.85%ROE
1.90652wk Low
10.29%Amplitude
100.00%Gross Margin
153.47MMarket Cap
-6.00Reward/Risk
5.33%Risk Rate
TradingKey Stock Score of VolitionRX Ltd
Currency: USD Updated: 2026-07-02Key Insights
VolitionRX Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 139 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.97.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
VolitionRX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
VolitionRX Ltd Highlights
StrengthsRisks
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 122.80% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.73M.
Overvalued
The company’s latest PE is -0.33, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.13M shares, decreasing 15.69% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.83.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
16.966
Target Price
+1147.50%
Upside Space
VolitionRX Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
VolitionRX Ltd Info
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Ticker SymbolVNRX
CompanyVolitionRX Ltd
CEOButera (Salvatore Thomas)
Websitehttps://volition.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of VolitionRX Ltd (VNRX)?
The current price of VolitionRX Ltd (VNRX) is 1.40.
What is the symbol of VolitionRX Ltd?
The ticker symbol of VolitionRX Ltd is VNRX.
What is the 52-week high of VolitionRX Ltd?
The 52-week high of VolitionRX Ltd is 18.80.
What is the 52-week low of VolitionRX Ltd?
The 52-week low of VolitionRX Ltd is 1.91.
What is the market capitalization of VolitionRX Ltd?
The market capitalization of VolitionRX Ltd is 153.47M.
Is VolitionRX Ltd (VNRX) currently rated as Buy, Hold, or Sell?
According to analysts, VolitionRX Ltd (VNRX) has an overall rating of Buy, with a price target of 16.97.
What is the Earnings Per Share (EPS TTM) of VolitionRX Ltd (VNRX)?
The Earnings Per Share (EPS TTM) of VolitionRX Ltd (VNRX) is -4.37.